LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL

BACKGROUND: Tovorafenib is an investigational, selective, CNS-penetrant, type II RAF inhibitor. The ongoing FIREFLY-1 (NCT04775485) phase 2 study (Kilburn LK, et al. Nat Med. 2023) of tovorafenib in BRAF -altered pLGG resulted in antitumor activity and manageable safety. Decreased growth velocity (G...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-06, Vol.26 (Suppl 4), p.0-0
Main Authors: Kline, Cassie, Waanders, Angela J, Ziegler, David S, Kilburn, Lindsay B, Nysom, Karsten, van der Lugt, Jasper, Hassall, Timothy E, Gerber, Nicolas U, Segal, Devorah, Larouche, Valérie, Khuong-Quang, Dong-Anh, Hansford, Jordan R, Leary, Sarah E S, Driever, Pablo Hernáiz, Bailey, Simon, Perreault, Sébastien, McCowage, Geoffrey, Witt, Olaf, Baxter, Patricia A, Kang, Hyoung Jin, Han, Jung Woo, Hargrave, Darren, Franson, Andrea T, Oren, Michal Yalon, Toledano, Helen, Abdelbaki, Mohamed S, Jabado, Nada, Gottardo, Nicholas G, Whipple, Nicholas S, Chi, Susan N, Oren, Liat, Tan, Enrica E K, Mueller, Sabine, Wright, Karen D, Blackman, Samuel C, Qiu, Jiaheng, Podesta, Dolores, Walter, Ashley, Da Costa, Daniel, Manley, Peter, McLeod, Lisa, Landi, Daniel B
Format: Article
Language:English
Subjects:
Final category: Low Grade Glioma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Tovorafenib is an investigational, selective, CNS-penetrant, type II RAF inhibitor. The ongoing FIREFLY-1 (NCT04775485) phase 2 study (Kilburn LK, et al. Nat Med. 2023) of tovorafenib in BRAF -altered pLGG resulted in antitumor activity and manageable safety. Decreased growth velocity (GV) was observed; this is an update on GV changes in skeletally immature children receiving tovorafenib. Methods A planned safety analysis was completed on August 8, 2023 on 137 patients (Arm 1: 77 & Arm 2: 60). Additional follow-up on all cases of decreased GV (an AESI) reported to the global safety database (GSDB) as of January 19, 2024 is provided. Results Overall, 29% had decreased GV from baseline (BL); 19% had ≥50% decrease. Of the 40 with this AESI, 75% had pre-existing neuromuscular or endocrine comorbidities potentially affecting normal growth, including 6 on GnRH-analogues for precocious puberty and 9 with BL heights 2 SDs above/below average for age and sex. Nineteen had on-treatment bone age assessments; none showed bone age advancement from BL or premature growth plate closure. No osteopenia or abnormal fractures reported. All 10 who discontinued or interrupted tovorafenib for ≥3 months for any reason (mean follow-up: 5.8 months), with off-treatment growth measurements available, showed post-treatment annualized GV (AGV) recovery (average AGV: on-treatment, 1.1 cm/y; off-treatment, 8 cm/y), with some exceeding expected average AGV for age. A 4-year-old boy with 1.2 cm/y AGV on-treatment had 12.3 cm/y AGV off-treatment (follow-up: 2 months). Five additional events of decreased GV in patients not on study FIREFLY-1 were reported to the GSDB; 4 of 5 had ≥3 months of off-treatment follow-up, all 4 recovered GV. Conclusions Decreased GV has been observed in patients on tovorafenib. Preliminary follow-up data in those who interrupted treatment show consistent evidence of GV recovery and preservation of growth potential on bone age studies.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noae064.431